Formulation Development
Abzena & BioXpress Therapeutics Announce Development & Manufacturing Partnership
Abzena and BioXpress Therapeutics recently announced their partnership to support biosimilar development for third-party customers. The partnership creates an….
Entasis Therapeutics & Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial
Entasis Therapeutics Holdings Inc. and Zai Lab Limited recently announced that patient enrollment in the ATTACK Phase 3 registrational clinical trial of sulbactam-durlobactam (SUL-DUR) is…
AC Immune Acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) Anti-Alpha-Synuclein Programs Targeting Neurodegenerative Diseases
AFFiRiS AG recently announced that AC Immune SA is acquiring AFFiRiS’ anti-alpha-synuclein programs targeting neurodegenerative diseases caused by misfolded forms of human self-proteins. All acquired…
Dyadic Announces Technology Transfer & Licensing Agreement With South Africa’s Rubic Consortium
Dyadic International, Inc. recently announced it signed a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium, a South African-based company whose mission…
ValenzaBio Partners With ProBioGen to Maximize Cell Line Productivity & Licenses GlymaxX
ProBioGen and ValenzaBio recently announced the initiation of a cell line development project involving the application of ProBioGen's proprietary GlymaxX technology. ValenzaBio's VB119 is a…
LEXEO Therapeutics Receives Rare Pediatric Disease Designation & Orphan Drug Designation
LEXEO Therapeutics recently announced that the US FDA has granted Rare Pediatric Disease designation and Orphan Drug designation to LX1004 for the treatment of CLN2…
Catalent Launches New OptiDose Design Solution to Help Create Differentiated Treatments That Are Successful for Innovators, Patients & Health Care Professionals
Catalent recently announced the launch of its new OptiDose Design Solution, at the Controlled Release Society (CRS) annual meeting, which is took place virtually from July…
AMRI Becomes Curia
Albany Molecular Research, Inc. (AMRI), a leading global contract research, development and manufacturing organization serving the pharmaceutical and biopharmaceutical industries, today announced that it is…
Catalent Plans Multi-Phase, $100 Million Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe
SOMERSET, N.J. – July 21, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and…
Strathclyde University conclude that membrane technology could revolutionize vaccine and therapeutics production
Whilst paying tribute to to the hugely impressive efforts of those who reconfigured existing equipment at speed into a "Generation 1" manufacturing process for mRNA…
Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve ZydisR Formulation for Cannabidiol as an Anesthesia Premedication
Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve ZydisR Formulation for Cannabidiol as an Anesthesia Premedication Catalent, the leading global provider of advanced delivery…
Curia, the former AMRI, to Acquire Integrity Bio, Expanding Its Biologic Formulation and Fill-Finish Capabilities
One day after announcing its name change to Curia, leading contract research, development and manufacturing organization AMRI reported it has entered into a definitive agreement…
Collaboration Between AbbVie, Biogen & Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health & Disease
Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence…
Cyclerion Therapeutics & Beacon Biosignals Announce Expanded Strategic Partnership
Cyclerion Therapeutics, Inc. and Beacon Biosignals recently announced an extended and expanded strategic partnership between the two companies. This collaboration is expected to identify disease-relevant…
Roquette Earns USDA Certified Biobased Product Label for BIOSUCCINIUM
Roquette recently announced it has earned the US Department of Agriculture (USDA) Certified Biobased Product label. The product, BIOSUCCINIUM® succinic acid, is now able to…
Evaxion Biotech Reports Data From Phase 1/2a Trials of EVX-01 & EVX-02
Evaxion Biotech A/S recently announced results from both its Phase 1/2a trial of cancer immunotherapy EVX-01 in metastatic melanoma and interim Phase 1/2a trial of…
Ensysce Biosciences Receives Notice of Award for Year 3 of Multi-Year NIDA Grant for the Clinical Development of its Next-Generation Opioid Products With Overdose Protection
Ensysce Biosciences, Inc. recently announced receipt of the third year award of a multi-year grant from the National Institute on Drug Abuse (NIDA). This award…
Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate
Valneva SE recently announced it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the US FDA. Breakthrough Therapy Designation…
Akston Biosciences Announces Positive Phase 1 Data for Second-Generation COVID-19 Vaccine Candidate
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, recently announced positive results from a 60-subject, open-label, Phase 1 trial of AKS-452, its…
LGM Pharma Launches New Stand-Alone Analytical Services Offering for Drug Developers & Manufacturers
LGM Pharma, a long-time leader in API sourcing, completed a transformational acquisition last year of long-established CDMO NexGen Pharma. Among the many new capabilities LGM…
